{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:16:30Z","timestamp":1790813790294,"version":"4.1.0"},"reference-count":40,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"2","funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["249835"],"award-info":[{"award-number":["249835"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RBUCE-UP","award":["00001002483\/78"],"award-info":[{"award-number":["00001002483\/78"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>A novel painkiller nanomedicine triggers the specific delivery of enkephalin neuropeptide into inflamed tissues.<\/jats:p>","DOI":"10.1126\/sciadv.aau5148","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T19:18:44Z","timestamp":1550085524000},"source":"Crossref","is-referenced-by-count":90,"title":["A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine"],"prefix":"10.1126","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6128-851X","authenticated-orcid":true,"given":"Jiao","family":"Feng","sequence":"first","affiliation":[{"name":"Institut Galien Paris-Sud, UMR8612, Univ. Paris-Sud, Universit\u00e9 Paris-Saclay, Ch\u00e2tenay-Malabry 92290, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-7869","authenticated-orcid":true,"given":"Sinda","family":"Lepetre-Mouelhi","sequence":"additional","affiliation":[{"name":"Institut Galien Paris-Sud, UMR8612, Univ. Paris-Sud, Universit\u00e9 Paris-Saclay, Ch\u00e2tenay-Malabry 92290, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0959-4461","authenticated-orcid":true,"given":"Anne","family":"Gautier","sequence":"additional","affiliation":[{"name":"Institut Galien Paris-Sud, UMR8612, Univ. Paris-Sud, Universit\u00e9 Paris-Saclay, Ch\u00e2tenay-Malabry 92290, France."},{"name":"Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Universit\u00e9 Paris Descartes, 75014 Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0310-8052","authenticated-orcid":true,"given":"Simona","family":"Mura","sequence":"additional","affiliation":[{"name":"Institut Galien Paris-Sud, UMR8612, Univ. Paris-Sud, Universit\u00e9 Paris-Saclay, Ch\u00e2tenay-Malabry 92290, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5773-3190","authenticated-orcid":true,"given":"Catherine","family":"Cailleau","sequence":"additional","affiliation":[{"name":"Institut Galien Paris-Sud, UMR8612, Univ. Paris-Sud, Universit\u00e9 Paris-Saclay, Ch\u00e2tenay-Malabry 92290, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Coudore","sequence":"additional","affiliation":[{"name":"Laboratoire de Neuropharmacologie, INSERM UMRS 1178, Univ. Paris-Sud, Universit\u00e9 Paris-Saclay, Ch\u00e2tenay-Malabry 92290, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6579-1849","authenticated-orcid":true,"given":"Michel","family":"Hamon","sequence":"additional","affiliation":[{"name":"Centre de Psychiatrie et Neurosciences, INSERM UMR 894, Universit\u00e9 Paris Descartes, 75014 Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7961-5443","authenticated-orcid":true,"given":"Patrick","family":"Couvreur","sequence":"additional","affiliation":[{"name":"Institut Galien Paris-Sud, UMR8612, Univ. Paris-Sud, Universit\u00e9 Paris-Saclay, Ch\u00e2tenay-Malabry 92290, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-770"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00008-4"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4867"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568026043451618","article-title":"Opioid receptors and their ligands","volume":"4","author":"Anna J.","year":"2004","unstructured":"J. Anna, F. Jakub, J. Tomasz, Opioid receptors and their ligands. Curr. Top. Med. Chem. 4, 1\u201317 (2004).","journal-title":"Curr. Top. Med. Chem."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.conb.2004.05.005","article-title":"Mu opioid receptor: A gateway to drug addiction","volume":"14","author":"Contet C.","year":"2004","unstructured":"C. Contet, B. L. Kieffer, K. Befort, Mu opioid receptor: A gateway to drug addiction. Curr. Opin. Neurobiol. 14, 370\u2013378 (2004).","journal-title":"Curr. Opin. Neurobiol."},{"key":"e_1_3_2_7_2","first-page":"1096","article-title":"Sympathoadrenal, cardiovascular and blood gas responses to highly selective mu and delta opioid peptides","volume":"251","author":"Kiritsy-Roy J. A.","year":"1989","unstructured":"J. A. Kiritsy-Roy, L. Marson, G. R. Van Loon, Sympathoadrenal, cardiovascular and blood gas responses to highly selective mu and delta opioid peptides. J. Pharmacol. Exp. Ther. 251, 1096\u20131103 (1989).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_8_2","first-page":"91","article-title":"Role of peripheral mu, delta and kappa opioid receptors in opioid-induced inhibition of gastrointestinal transit in rats","volume":"254","author":"Tavani A.","year":"1990","unstructured":"A. Tavani, P. Petrillo, A. La Regina, M. Sbacchi, Role of peripheral mu, delta and kappa opioid receptors in opioid-induced inhibition of gastrointestinal transit in rats. J. Pharmacol. Exp. Ther. 254, 91\u201397 (1990).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s00213-002-1100-8","article-title":"Antinociceptive effects of the selective delta opioid agonist SNC80 alone and in combination with mu opioids in the squirrel monkey titration procedure","volume":"163","author":"Dykstra L.","year":"2002","unstructured":"L. Dykstra, A. L. Granger, R. M. Allen, X. Zhang, K. C. Rice, Antinociceptive effects of the selective delta opioid agonist SNC80 alone and in combination with mu opioids in the squirrel monkey titration procedure. Psychopharmacology (Berl) 163, 420\u2013429 (2002).","journal-title":"Psychopharmacology (Berl)"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrcardio.2016.200","article-title":"Long-term neprilysin inhibition\u2014Implications for ARNIs","volume":"14","author":"Campbell D. J.","year":"2016","unstructured":"D. J. Campbell, Long-term neprilysin inhibition\u2014Implications for ARNIs. Nat. Rev. Cardiol. 14, 171\u2013186 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.2174\/092986712803251548","article-title":"Peptides as therapeutics with enhanced bioactivity","volume":"19","author":"Goodwin D.","year":"2012","unstructured":"D. Goodwin, P. Simerska, I. Toth, Peptides as therapeutics with enhanced bioactivity. Curr. Med. Chem. 19, 4451\u20134461 (2012).","journal-title":"Curr. Med. Chem."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0168-3659(97)00061-8","article-title":"Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood\u2013brain barrier using surfactant-coated nanoparticles","volume":"49","author":"Kreuter J.","year":"1997","unstructured":"J. Kreuter, V. E. Petrov, D. A. Kharkevich, R. N. Alyautdin, Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood\u2013brain barrier using surfactant-coated nanoparticles. J. Control. Release 49, 81\u201387 (1997).","journal-title":"J. Control. Release"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/0885328211429495","article-title":"Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood\u2013brain barrier","volume":"27","author":"Chen Y.-C.","year":"2013","unstructured":"Y.-C. Chen, W.-Y. Hsieh, W.-F. Lee, D.-T. Zeng, Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood\u2013brain barrier. J. Biomater. Appl. 27, 909\u2013922 (2013).","journal-title":"J. Biomater. Appl."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jconrel.2014.10.028","article-title":"Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration","volume":"197","author":"Lalatsa A.","year":"2015","unstructured":"A. Lalatsa, A. G. Sch\u00e4tzlein, N. L. Garrett, J. Moger, M. Briggs, L. Godfrey, A. Iannitelli, J. Freeman, I. F. Uchegbu, Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration. J. Control. Release 197, 87\u201396 (2015).","journal-title":"J. Control. Release"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ejpb.2013.06.005","article-title":"Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes","volume":"85","author":"Popov M.","year":"2013","unstructured":"M. Popov, I. Abu Hammad, T. Bachar, S. Grinberg, C. Linder, D. Stepensky, E. Heldman, Delivery of analgesic peptides to the brain by nano-sized bolaamphiphilic vesicles made of monolayer membranes. Eur. J. Pharm. Biopharm. 85, 381\u2013389 (2013).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/mp300009u","article-title":"A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine5-enkephalin, to the brain","volume":"9","author":"Lalatsa A.","year":"2012","unstructured":"A. Lalatsa, V. Lee, J. P. Malkinson, M. Zloh, A. G. Sch\u00e4tzlein, I. F. Uchegbu, A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine5-enkephalin, to the brain. Mol. Pharm. 9, 1665\u20131680 (2012).","journal-title":"Mol. Pharm."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood\u2013brain barrier by nanoparticles","volume":"161","author":"Wohlfart S.","year":"2012","unstructured":"S. Wohlfart, S. Gelperina, J. Kreuter, Transport of drugs across the blood\u2013brain barrier by nanoparticles. J. Control. Release 161, 264\u2013273 (2012).","journal-title":"J. Control. Release"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm908"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"E217","DOI":"10.1073\/pnas.1313459110","article-title":"A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity","volume":"111","author":"Maksimenko A.","year":"2014","unstructured":"A. Maksimenko, F. Dosio, J. Mougin, A. Ferrero, S. Wack, L. H. Reddy, A.-A. Weyn, E. Lepeltier, C. Bourgaux, B. Stella, L. Cattel, P. Couvreur, A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc. Natl. Acad. Sci. U.S.A. 111, E217\u2013E226 (2014).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1021\/jo0706123","article-title":"Pd\u2212C-induced catalytic transfer hydrogenation with triethylsilane","volume":"72","author":"Mandal P. K.","year":"2007","unstructured":"P. K. Mandal, J. S. McMurray, Pd\u2212C-induced catalytic transfer hydrogenation with triethylsilane. J. Org. Chem. 72, 6599\u20136601 (2007).","journal-title":"J. Org. Chem."},{"key":"e_1_3_2_21_2","first-page":"587","article-title":"Liposomal formulation and characterization of the opioid peptide leucine enkephalin","volume":"3","author":"Betageri G. V.","year":"2011","unstructured":"G. V. Betageri, N. B. Vutla, A. K. Banga, Liposomal formulation and characterization of the opioid peptide leucine enkephalin. Pharm. Pharmacol. Commun. 3, 587\u2013591 (2011).","journal-title":"Pharm. Pharmacol. Commun."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/bip.21013","article-title":"Effect of formulation factors on incorporation of the hydrophilic peptide dalargin into PLGA and mPEG-PLGA nanoparticles","volume":"90","author":"Chen Y.","year":"2008","unstructured":"Y. Chen, F. Wang, H. A. E. Benson, Effect of formulation factors on incorporation of the hydrophilic peptide dalargin into PLGA and mPEG-PLGA nanoparticles. Biopolymers 90, 644\u2013650 (2008).","journal-title":"Biopolymers"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-015-8535-3"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(88)90026-7"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.neuropharm.2005.03.014","article-title":"Dissection of peripheral and central endogenous opioid modulation of systemic interleukin-1\u03b2 responses using c-fos expression in the rat brain","volume":"49","author":"Buller K. M.","year":"2005","unstructured":"K. M. Buller, A. S. Hamlin, P. B. Osborne, Dissection of peripheral and central endogenous opioid modulation of systemic interleukin-1\u03b2 responses using c-fos expression in the rat brain. Neuropharmacology 49, 230\u2013242 (2005).","journal-title":"Neuropharmacology"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.copbio.2006.10.002","article-title":"Therapeutic peptides: Technological advances driving peptides into development","volume":"17","author":"Sato A. K.","year":"2006","unstructured":"A. K. Sato, M. Viswanathan, R. B. Kent, C. R. Wood, Therapeutic peptides: Technological advances driving peptides into development. Curr. Opin. Biotechnol. 17, 638\u2013642 (2006).","journal-title":"Curr. Opin. Biotechnol."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1021\/nl061942q","article-title":"Squalenoyl nanomedicines as potential therapeutics","volume":"6","author":"Couvreur P.","year":"2006","unstructured":"P. Couvreur, B. Stella, L. H. Reddy, H. Hillaireau, C. Dubernet, D. Desma\u00eble, S. Lep\u00eatre-Mouelhi, F. Rocco, N. Dereuddre-Bosquet, P. Clayette, V. Rosilio, V. Marsaud, J.-M. Renoir, L. Cattel, Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 6, 2544\u20132548 (2006).","journal-title":"Nano Lett."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2014.274"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/261423a0","article-title":"Evidence for analgesic activity of enkephalin in the mouse","volume":"261","author":"B\u00fcscher H. H.","year":"1976","unstructured":"H. H. B\u00fcscher, R. C. Hill, D. R\u00d6Mer, F. Cardinaux, A. Closse, D. Hauser, J. Pless, Evidence for analgesic activity of enkephalin in the mouse. Nature 261, 423\u2013425 (1976).","journal-title":"Nature"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/0250-474X.40347","article-title":"Effect of some clinically used proteolytic enzymes on Inflammation in rats","volume":"70","author":"Viswanatha Swamy A. H. M.","year":"2008","unstructured":"A. H. M. Viswanatha Swamy, P. A. Patil, Effect of some clinically used proteolytic enzymes on Inflammation in rats. Indian J. Pharm. Sci. 70, 114\u2013117 (2008).","journal-title":"Indian J. Pharm. Sci."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1021\/nn204928v","article-title":"Self-assembled squalenoylated penicillin bioconjugates: An original approach for the treatment of intracellular infections","volume":"6","author":"S\u00e9miramoth N.","year":"2012","unstructured":"N. S\u00e9miramoth, C. Di Meo, F. Zouhiri, F. Sa\u00efd-Hassane, S. Valetti, R. Gorges, V. Nicolas, J. H. Poupaert, S. Chollet-Martin, D. Desma\u00eble, R. Gref, P. Couvreur, Self-assembled squalenoylated penicillin bioconjugates: An original approach for the treatment of intracellular infections. ACS Nano 6, 3820\u20133831 (2012).","journal-title":"ACS Nano"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejps.2009.02.012","article-title":"Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis","volume":"37","author":"Sim\u00f5es M. F.","year":"2009","unstructured":"M. F. Sim\u00f5es, E. Valente, M. J. R. G\u00f3mez, E. Anes, L. Constantino, Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis. Eur. J. Pharm. Sci. 37, 257\u2013263 (2009).","journal-title":"Eur. J. Pharm. Sci."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/cr5004634"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0169-409X(95)00110-S","article-title":"Prodrugs of peptides and peptidomimetics for improved formulation and delivery","volume":"19","author":"Oliyai R.","year":"1996","unstructured":"R. Oliyai, Prodrugs of peptides and peptidomimetics for improved formulation and delivery. Adv. Drug Deliv. Rev. 19, 275\u2013286 (1996).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/jnr.23768","article-title":"Animal models of chronic pain: Advances and challenges for clinical translation","volume":"95","author":"Burma N. E.","year":"2016","unstructured":"N. E. Burma, H. Leduc-Pessah, C. Y. Fan, T. Trang, Animal models of chronic pain: Advances and challenges for clinical translation. J. Neurosci. Res. 95, 1242\u20131256 (2016).","journal-title":"J. Neurosci. Res."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0040-4039(00)71112-9","article-title":"The selective oxidation of the terminal double bonds in squalene","volume":"3","author":"van Tamelen E. E.","year":"1962","unstructured":"E. E. van Tamelen, T. J. Curphey, The selective oxidation of the terminal double bonds in squalene. Tetrahedron Lett. 3, 121\u2013124 (1962).","journal-title":"Tetrahedron Lett."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1021\/jm501224x","article-title":"Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: Synthesis and proof of concept","volume":"58","author":"Skarbek C.","year":"2014","unstructured":"C. Skarbek, L. L. Lesueur, H. Chapuis, A. Deroussent, C. Pioche-Durieu, A. Daville, J. Caron, M. Rivard, T. Martens, J.-R. Bertrand, E. Le Cam, G. Vassal, P. Couvreur, D. Desmaele, A. Paci, Preactivated oxazaphosphorines designed for isophosphoramide mustard delivery as bulk form or nanoassemblies: Synthesis and proof of concept. J. Med. Chem. 58, 705\u2013717 (2014).","journal-title":"J. Med. Chem."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90201-4"},{"key":"e_1_3_2_39_2","first-page":"369","article-title":"Anti-inflammatory and antipyretic activities of indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-indole-3-acetic acid","volume":"141","author":"Winter C. A.","year":"1963","unstructured":"C. A. Winter, E. A. Risley, G. W. Nuss, Anti-inflammatory and antipyretic activities of indomethacin, 1-(p-chlorobenzoyl)-5-methoxy-2-methyl-indole-3-acetic acid. J. Pharmacol. Exp. Ther. 141, 369\u2013376 (1963).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0306-4522(94)90250-X","article-title":"The role of nitric oxide in the development and maintenance of the hyperalgesia produced by intraplantar injection of carrageenan in the rat","volume":"60","author":"Meller S. T.","year":"1994","unstructured":"S. T. Meller, C. P. Cummings, R. J. Traub, G. F. Gebhart, The role of nitric oxide in the development and maintenance of the hyperalgesia produced by intraplantar injection of carrageenan in the rat. Neuroscience 60, 367\u2013374 (1994).","journal-title":"Neuroscience"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00503931","article-title":"Caerulein and morphine in a model of visceral pain","volume":"319","author":"Brasch H.","year":"1982","unstructured":"H. Brasch, G. Zetler, Caerulein and morphine in a model of visceral pain. Naunyn Schmiedebergs Arch. Pharmacol. 319, 161\u2013167 (1982).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.aau5148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T13:42:00Z","timestamp":1704807720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.aau5148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1126\/sciadv.aau5148"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.aau5148","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]},"article-number":"eaau5148"}}